Reasonable questions...
This only really works if there is potential for the BP beyond the current indication and/or formulation (ie. MND-2119, FDC, etc.). This gives BP huge future potential.
However, the generic competition still exists in the U.S.
So, why not have Amarin roll out their AG to pound away at the other generics by undercutting THEM.
Amarin and the BP team up on API purchase to make it less expensive for both.
Amarin has no overhead because they no longer need sales force, R&D, big corporate offices, etc. because all they are doing is distributing a generic.